Moderna Announces Supply Agreement with the Ministry of Public Health to Supply Qatar with mRNA Vaccine Against COVID-19 (mRNA-1273)
Moderna Announces Supply Agreement with the Ministry of Public Health to Supply Qatar with
mRNA Vaccine Against COVID-19 (mRNA-1273)
October 26, 2020
Supply agreement reflects Moderna’s commitment to make its vaccine available in Qatar
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 26, 2020-- Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA
(mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced a supply agreement with the
Ministry of Public Health of Qatar for mRNA-1273, Moderna’s vaccine candidate against COVID-19, to support the Ministry’s ongoing efforts to secure
early access to a safe and effective COVID-19 vaccine for the people of Qatar.
“We appreciate the confidence of the Ministry of Health of Qatar in our mRNA vaccine platform and the collaboration we have had to date,” said
Stéphane Bancel, Moderna’s Chief Executive Officer. “We are advancing the clinical development of mRNA-1273 with our Phase 3 COVE study, which
is now fully enrolled with a representative demography of participants across ages, ethnicities and high-risk populations. In parallel we are scaling up
our manufacturing capability with our strategic partners, Lonza and Rovi, to address this global health emergency by delivering a safe and effective
vaccine to the people of Qatar and around the world.”
The Phase 1 interim analysis showed that mRNA-1273 was generally well-tolerated across all age groups and induced rapid and strong immune
responses against SARS-CoV-2. mRNA-1273 is currently being studied in a Phase 3 randomized, 1:1 placebo-controlled trial of 30,000 participants at
the 100 μg dose level in the U.S. On Thursday, October 22, Moderna completed enrollment of the Phase 3 COVE study. For more information about
the COVE study, click here. mRNA-1273 currently is not approved for use by any regulatory body.
Moderna is scaling up global manufacturing to be able to deliver approximately 500 million doses per year and possibly up to 1 billion doses per year,
beginning in 2021.
Over the past nine years, Moderna has invested in creating and developing a novel platform for designing and manufacturing a new class of
mRNA-based vaccines. The investments in this proprietary platform have enabled Moderna to expeditiously create, manufacture and clinically
develop mRNA-1273 to potentially address the current COVID-19 pandemic.
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are
designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have
the potential to address a broad spectrum of diseases. The company’s platform builds on continuous advances in basic and applied mRNA science,
delivery technology and manufacturing, providing Moderna the capability to pursue in parallel a robust pipeline of new development candidates.
Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases,
independently and with strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca PLC and Merck & Co.,
Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense, and the Biomedical
Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR)
within the U.S. Department of Health and Human Services (HHS). Moderna has been named a top biopharmaceutical employer by Science for the
past five years. To learn more, visit www.modernatx.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended,
including statements regarding: the Company’s development of a potential vaccine against the novel coronavirus (mRNA-1273), the potential for
mRNA-1273 to prevent COVID-19 disease and slow the spread of SARS-CoV-2, the terms of the Company’s supply of mRNA-1273 to the Ministry of
Public Health of Qatar, and the timing for the manufacturing, supply and distribution of mRNA-1273. In some cases, forward-looking statements can be
identified by terminology such as “will,” “may,” “should,” “could,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,”
“potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these
words. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these
forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna’s
control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks,
uncertainties, and other factors include, among others: preclinical and clinical development is lengthy and uncertain, especially for a new class of
medicines such as mRNA, and therefore our preclinical programs or development candidates may be delayed, terminated, or may never advance to or
in the clinic; no commercial product using mRNA technology has been approved and may never be approved; mRNA drug development has
substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new class of medicines; despite having
ongoing interactions with the FDA or other regulatory agencies, the FDA or such other regulatory agencies may not agree with the Company’s
regulatory approval strategies, components of our filings, such as clinical trial designs, conduct and methodologies, or the sufficiency of data
submitted; the fact that the rapid response technology in use by Moderna is still being developed and implemented; potential adverse impacts due to
the global COVID-19 pandemic such as delays in clinical trials, preclinical work, overall operations, regulatory review, manufacturing and supply chain
interruptions, adverse effects on healthcare systems and disruption of the global economy; and those risks and uncertainties described under the
heading “Risk Factors” in Moderna’s most recent Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (SEC) and
in subsequent filings made by Moderna with the SEC, which are available on the SEC’s website at www.sec.gov. Except as required by law, Moderna
disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new
information, future developments or otherwise. These forward-looking statements are based on Moderna’s current expectations and speak only as of
the date hereof.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005485/en/
Director, Corporate Communications
Head of Investor Relations